Interpretation of retrospective data evaluating high‐dose methotrexate as central nervous system prophylaxis in diffuse large B‐cell lymphoma; caution required
Open Access
- 29 May 2021
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 96 (9) , E338-E339
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphomaAmerican Journal of Hematology, 2021
- Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryBlood Advances, 2020
- Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphomaAnnals of Hematology, 2020
- Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicityBritish Journal of Haematology, 2019
- Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapseLeukemia & Lymphoma, 2019
- Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab eraBritish Journal of Haematology, 2014
- A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaBritish Journal of Cancer, 2014